- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02149108
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies.
연구 개요
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Amsterdam, 네덜란드
- 1199.52.3101 Boehringer Ingelheim Investigational Site
-
Amsterdam, 네덜란드
- 1199.52.3103 Boehringer Ingelheim Investigational Site
-
Utrecht, 네덜란드
- 1199.52.3102 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Kaohsiung, 대만
- 1199.52.8805 Boehringer Ingelheim Investigational Site
-
Taipei, 대만
- 1199.52.8801 Boehringer Ingelheim Investigational Site
-
Taipei, 대만
- 1199.52.8803 Boehringer Ingelheim Investigational Site
-
Taoyuan County, 대만
- 1199.52.8802 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Goyang, 대한민국
- 1199.52.8202 Boehringer Ingelheim Investigational Site
-
Seoul, 대한민국
- 1199.52.8201 Boehringer Ingelheim Investigational Site
-
Seoul, 대한민국
- 1199.52.8203 Boehringer Ingelheim Investigational Site
-
Seoul, 대한민국
- 1199.52.8204 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Herning, 덴마크
- 1199.52.4502 Boehringer Ingelheim Investigational Site
-
København Ø, 덴마크
- 1199.52.4501 Boehringer Ingelheim Investigational Site
-
Næstved, 덴마크
- 1199.52.4503 Boehringer Ingelheim Investigational Site
-
Odense C, 덴마크
- 1199.52.4504 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Dresden, 독일
- 1199.52.4906 Boehringer Ingelheim Investigational Site
-
Essen, 독일
- 1199.52.4905 Boehringer Ingelheim Investigational Site
-
Freiburg, 독일
- 1199.52.4904 Boehringer Ingelheim Investigational Site
-
Mannheim, 독일
- 1199.52.4903 Boehringer Ingelheim Investigational Site
-
Ulm, 독일
- 1199.52.4901 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Moscow, 러시아 연방
- 1199.52.0701 Boehringer Ingelheim Investigational Site
-
Moscow, 러시아 연방
- 1199.52.0703 Boehringer Ingelheim Investigational Site
-
St. Petersburg, 러시아 연방
- 1199.52.0702 Boehringer Ingelheim Investigational Site
-
Tyumen, 러시아 연방
- 1199.52.0707 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Mexico, 멕시코
- 1199.52.5201 Boehringer Ingelheim Investigational Site
-
-
-
-
California
-
Los Angeles, California, 미국
- 1199.52.0108 Boehringer Ingelheim Investigational Site
-
-
Connecticut
-
New Haven, Connecticut, 미국
- 1199.52.0105 Boehringer Ingelheim Investigational Site
-
Plainville, Connecticut, 미국
- 1199.52.0101 Boehringer Ingelheim Investigational Site
-
-
Illinois
-
Arlington Heights, Illinois, 미국
- 1199.52.0121 Boehringer Ingelheim Investigational Site
-
-
Iowa
-
Sioux City, Iowa, 미국
- 1199.52.0123 Boehringer Ingelheim Investigational Site
-
-
Kansas
-
Topeka, Kansas, 미국
- 1199.52.0104 Boehringer Ingelheim Investigational Site
-
-
Louisiana
-
New Orleans, Louisiana, 미국
- 1199.52.0114 Boehringer Ingelheim Investigational Site
-
-
Michigan
-
Detroit, Michigan, 미국
- 1199.52.0113 Boehringer Ingelheim Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, 미국
- 1199.52.0125 Boehringer Ingelheim Investigational Site
-
-
New York
-
Johnson City, New York, 미국
- 1199.52.0119 Boehringer Ingelheim Investigational Site
-
-
Ohio
-
Canton, Ohio, 미국
- 1199.52.0115 Boehringer Ingelheim Investigational Site
-
Sylvania, Ohio, 미국
- 1199.52.0106 Boehringer Ingelheim Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, 미국
- 1199.52.0102 Boehringer Ingelheim Investigational Site
-
-
Texas
-
Fort Worth, Texas, 미국
- 1199.52.0120 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Aalst, 벨기에
- 1199.52.3208 Boehringer Ingelheim Investigational Site
-
Bonheiden, 벨기에
- 1199.52.3205 Boehringer Ingelheim Investigational Site
-
Bruxelles, 벨기에
- 1199.52.3202 Boehringer Ingelheim Investigational Site
-
Charleroi, 벨기에
- 1199.52.3207 Boehringer Ingelheim Investigational Site
-
Edegem, 벨기에
- 1199.52.3204 Boehringer Ingelheim Investigational Site
-
Haine-Saint-Paul, 벨기에
- 1199.52.3203 Boehringer Ingelheim Investigational Site
-
Leuven, 벨기에
- 1199.52.3201 Boehringer Ingelheim Investigational Site
-
Liège, 벨기에
- 1199.52.3206 Boehringer Ingelheim Investigational Site
-
Luxembourg, 벨기에
- 1199.52.3521 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Stockholm, 스웨덴
- 1199.52.4601 Boehringer Ingelheim Investigational Site
-
Uppsala, 스웨덴
- 1199.52.4602 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Barcelona, 스페인
- 1199.52.3401 Boehringer Ingelheim Investigational Site
-
L'Hospitalet de Llobregat, 스페인
- 1199.52.3402 Boehringer Ingelheim Investigational Site
-
La Coruña, 스페인
- 1199.52.3406 Boehringer Ingelheim Investigational Site
-
Madrid, 스페인
- 1199.52.3403 Boehringer Ingelheim Investigational Site
-
Madrid, 스페인
- 1199.52.3404 Boehringer Ingelheim Investigational Site
-
Santander, 스페인
- 1199.52.3405 Boehringer Ingelheim Investigational Site
-
Sevilla, 스페인
- 1199.52.3407 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Cdad. de Córdoba, 아르헨티나
- 1199.52.5404 Boehringer Ingelheim Investigational Site
-
Cdad. de Córdoba, 아르헨티나
- 1199.52.5405 Boehringer Ingelheim Investigational Site
-
Ciudad Autónoma de Bs As, 아르헨티나
- 1199.52.5401 Boehringer Ingelheim Investigational Site
-
Ciudad Autónoma de Bs As, 아르헨티나
- 1199.52.5403 Boehringer Ingelheim Investigational Site
-
Ciudad Autónoma de Bs As, 아르헨티나
- 1199.52.5406 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Aberdeen, 영국
- 1199.52.4401 Boehringer Ingelheim Investigational Site
-
Manchester, 영국
- 1199.52.4403 Boehringer Ingelheim Investigational Site
-
Middlesex, 영국
- 1199.52.4402 Boehringer Ingelheim Investigational Site
-
Nottingham, 영국
- 1199.52.4405 Boehringer Ingelheim Investigational Site
-
Southampton, 영국
- 1199.52.4404 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Linz, 오스트리아
- 1199.52.4302 Boehringer Ingelheim Investigational Site
-
Wien, 오스트리아
- 1199.52.4303 Boehringer Ingelheim Investigational Site
-
Wien, 오스트리아
- 1199.52.4304 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Beer Sheva, 이스라엘
- 1199.52.9706 Boehringer Ingelheim Investigational Site
-
Petach Tikva, 이스라엘
- 1199.52.9704 Boehringer Ingelheim Investigational Site
-
Tel Aviv, 이스라엘
- 1199.52.9703 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Genova, 이탈리아
- 1199.52.3901 Boehringer Ingelheim Investigational Site
-
Milano, 이탈리아
- 1199.52.3906 Boehringer Ingelheim Investigational Site
-
Napoli, 이탈리아
- 1199.52.3907 Boehringer Ingelheim Investigational Site
-
Padova, 이탈리아
- 1199.52.3905 Boehringer Ingelheim Investigational Site
-
Pisa, 이탈리아
- 1199.52.3903 Boehringer Ingelheim Investigational Site
-
San Giovanni Rotondo (FG), 이탈리아
- 1199.52.3904 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Aichi, Nagoya, 일본
- 1199.52.8102 Boehringer Ingelheim Investigational Site
-
Chiba, Chiba, 일본
- 1199.52.8105 Boehringer Ingelheim Investigational Site
-
Chiba, Kashiwa, 일본
- 1199.52.8101 Boehringer Ingelheim Investigational Site
-
Ehime, Matsuyama, 일본
- 1199.52.8107 Boehringer Ingelheim Investigational Site
-
Fukuoka, Fukuoka, 일본
- 1199.52.8106 Boehringer Ingelheim Investigational Site
-
Hokkaido, Sapporo, 일본
- 1199.52.8108 Boehringer Ingelheim Investigational Site
-
Hyogo, Amagasaki, 일본
- 1199.52.8115 Boehringer Ingelheim Investigational Site
-
Hyogo, Kobe, 일본
- 1199.52.8112 Boehringer Ingelheim Investigational Site
-
Ibaraki, Tsukuba, 일본
- 1199.52.8114 Boehringer Ingelheim Investigational Site
-
Oita, Yufu, 일본
- 1199.52.8110 Boehringer Ingelheim Investigational Site
-
Osaka, Osaka, 일본
- 1199.52.8116 Boehringer Ingelheim Investigational Site
-
Osaka, Suita, 일본
- 1199.52.8103 Boehringer Ingelheim Investigational Site
-
Saitama, Kitaadachi-gun, 일본
- 1199.52.8109 Boehringer Ingelheim Investigational Site
-
Shizuoka, Sunto-gun, 일본
- 1199.52.8104 Boehringer Ingelheim Investigational Site
-
Tokyo , Shinagawa-ku, 일본
- 1199.52.8113 Boehringer Ingelheim Investigational Site
-
Tokyo, Koto-ku, 일본
- 1199.52.8111 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Brno, 체코
- 1199.52.4202 Boehringer Ingelheim Investigational Site
-
Hradec Kralove, 체코
- 1199.52.4204 Boehringer Ingelheim Investigational Site
-
Prague, 체코
- 1199.52.4201 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Adana, 칠면조
- 1199.52.9005 Boehringer Ingelheim Investigational Site
-
Ankara, 칠면조
- 1199.52.9001 Boehringer Ingelheim Investigational Site
-
Antalya, 칠면조
- 1199.52.9003 Boehringer Ingelheim Investigational Site
-
Istanbul, 칠면조
- 1199.52.9004 Boehringer Ingelheim Investigational Site
-
Izmir, 칠면조
- 1199.52.9002 Boehringer Ingelheim Investigational Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다
- 1199.52.1003 Boehringer Ingelheim Investigational Site
-
-
Ontario
-
Edmonton, Ontario, 캐나다
- 1199.52.1004 Boehringer Ingelheim Investigational Site
-
Toronto, Ontario, 캐나다
- 1199.52.1001 Boehringer Ingelheim Investigational Site
-
-
Quebec
-
Montreal, Quebec, 캐나다
- 1199.52.1002 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Almada, 포르투갈
- 1199.52.3504 Boehringer Ingelheim Investigational Site
-
Coimbra, 포르투갈
- 1199.52.3502 Boehringer Ingelheim Investigational Site
-
Loures, 포르투갈
- 1199.52.3505 Boehringer Ingelheim Investigational Site
-
Porto, 포르투갈
- 1199.52.3501 Boehringer Ingelheim Investigational Site
-
Porto, 포르투갈
- 1199.52.3506 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Jelenia Gora, 폴란드
- 1199.52.4801 Boehringer Ingelheim Investigational Site
-
Poznan, 폴란드
- 1199.52.4803 Boehringer Ingelheim Investigational Site
-
Wroclaw, 폴란드
- 1199.52.4804 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Lille cedex, 프랑스
- 1199.52.3304 Boehringer Ingelheim Investigational Site
-
Lyon cedex 8, 프랑스
- 1199.52.3307 Boehringer Ingelheim Investigational Site
-
Paris cedex 15, 프랑스
- 1199.52.3305 Boehringer Ingelheim Investigational Site
-
Reims Cedex, 프랑스
- 1199.52.3301 Boehringer Ingelheim Investigational Site
-
-
-
-
New South Wales
-
Concord, New South Wales, 호주
- 1199.52.6102 Boehringer Ingelheim Investigational Site
-
St Leonards, New South Wales, 호주
- 1199.52.6103 Boehringer Ingelheim Investigational Site
-
Wollongong, New South Wales, 호주
- 1199.52.6101 Boehringer Ingelheim Investigational Site
-
-
Victoria
-
Heidelberg, Victoria, 호주
- 1199.52.6104 Boehringer Ingelheim Investigational Site
-
-
Western Australia
-
Nedlands, Western Australia, 호주
- 1199.52.6105 Boehringer Ingelheim Investigational Site
-
Perth, Western Australia, 호주
- 1199.52.6106 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Hong Kong, 홍콩
- 1199.52.8501 Boehringer Ingelheim Investigational Site
-
Hong Kong, 홍콩
- 1199.52.8502 Boehringer Ingelheim Investigational Site
-
Hong Kong, 홍콩
- 1199.52.8503 Boehringer Ingelheim Investigational Site
-
Hong Kong, 홍콩
- 1199.52.8504 Boehringer Ingelheim Investigational Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria:
- Age >= 18 years
- Signed informed consent
- Histologically or cytologically confirmed colorectal adenocarcinoma
- Metastatic or locally advanced disease not amenable to curative surgery and/or radiotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status = 1
- At least one measurable lesion according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1
- Progression on standard therapies or withdrawn from standard treatment due to unacceptable toxicity. Previous standard treatment must include all of the following:
- - fluoropyrimidine
- - oxaliplatin: Patients treated with oxaliplatin in adjuvant setting should have progressed within 6 months of completion of adjuvant therapy or they must have been treated with oxaliplatin for metastatic disease
- - irinotecan
- - bevacizumab or aflibercept
- - cetuximab or panitumumab for patients with K-Ras wt or Ras wt tumours
- - The remaining standard available therapy as recommended by investigator is best supportive care (note: previous treatment with regorafenib and TAS 102 are allowed and these agents should be administered before study if available to patient according to local standards)
- - Life expectancy of at least 12 weeks
- - Hepatic function: aspartate aminotransferase (AST)/ Alanine Amino Transferase (ALT) = 1.5 X Upper Limit of Normal (ULN) and bilirubin = ULN for patients without liver metastases. AST/ALT = 2.5 X ULN and bilirubin = ULN for patients with liver metastases. Patients with Gilbert syndrome and bilirubin < 2 X ULN and normal AST/ALT are eligible
- Coagulation parameters: International normalised ratio (INR) < 2 and partial prothrombin Time (PTT) = 2xULN
Exclusion criteria:
- Previous treatment with nintedanib
- toxicity attributed to previous anticancer therapy that did not resolve to Common Terminology Criteria for Adverse Events (CTCAE) grade =1
- History of other malignancies in the last 5 years, in particular those that could interfere with interpretation of results.
- Serious concomitant disease or medical condition affecting compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug,
- Significant cardiovascular diseases
- History of severe haemorrhagic or thromboembolic event in the past 12 months
- Bleeding or thrombotic disorders requiring anticoagulant therapy such as warfarin, or similar agents requiring therapeutic INR monitoring
- Gastrointestinal disorders or abnormalities that would interfere with absorption of study drug
- Patient with brain metastases that are symptomatic and/or require therapy.
- Patients of childbearing potential who are sexually active and unwilling to use a highly effective method of contraception
- Pregnancy or breast-feeding.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Nintedanib (BIBF 1120) + BSC
|
|
위약 비교기: Placebo + BSC
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Progression-Free Survival (PFS) by Central Review Assessment
기간: From randomisation until cut-off date 14JUN2016.
|
PFS by central review assessment was defined as the time from the date of randomisation to the date of disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 or death from any cause, whichever occurred first. Median, 95% Confidence Interval were calculated from an unadjusted Kaplan-Meier curve for each treatment arm. |
From randomisation until cut-off date 14JUN2016.
|
Overall Survival (OS)
기간: From randomisation until cut-off date 14JUN2016.
|
OS was defined as the time from randomisation to the time of death from any cause. Median, 95% Confidence Interval were calculated from an unadjusted Kaplan-Meier curve for each treatment arm. |
From randomisation until cut-off date 14JUN2016.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Objective Tumour Response (Complete Response (CR)) + Partial Response (PR) by Central Review Assessment
기간: From randomisation until cut-off date 14JUN2016.
|
Objective tumour response was defined as best overall response of CR or PR determined by central review assessment.
|
From randomisation until cut-off date 14JUN2016.
|
Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment
기간: From randomisation until cut-off date 14JUN2016.
|
Disease control was defined as best overall response of CR, PR, or Stable Disease (SD).
|
From randomisation until cut-off date 14JUN2016.
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Van Cutsem E, Yoshino T, Lenz HJ, Lonardi S, Falcone A, Limon ML, Saunders M, Sobrero A, Park YS, Ferreiro R, Hong YS, Tomasek J, Taniguchi H, Ciardiello F, Stoehr J, Oum'Hamed Z, Vlassak S, Studeny M, Argiles G. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Ann Oncol. 2018 Sep 1;29(9):1955-1963. doi: 10.1093/annonc/mdy241.
- Van Cutsem E, Yoshino T, Hocke J, Oum'Hamed Z, Studeny M, Tabernero J. Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment. Clin Colorectal Cancer. 2016 Mar;15(1):91-94.e1. doi: 10.1016/j.clcc.2015.09.005. Epub 2015 Oct 9.
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
위약에 대한 임상 시험
-
AJU Pharm Co., Ltd.OM Pharma SA모병
-
University Hospital, Strasbourg, France모집하지 않고 적극적으로